Oral OTEZLA® (apremilast) Demonstrated Clinically Meaningful and Sustained Improvements in Skin, Nail and Scalp of Adult Patients with Moderate to Severe Plaque Psoriasis

[Business Wire] – Celgene Corporation today released new research findings on OTEZLA® , the Company’s oral, selective inhibitor of phosphodiesterase 4 , from the ESTE more

View todays social media effects on CELG

View the latest stocks trending across Twitter. Click to view dashboard

See who Celgene is hiring next, click here to view